Last reviewed 2026-04-20 · How we verify

PF-07328948 (pf-07328948)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Application site dermatitis
• Acute sinusitis
• Headache
• Neurological symptom
• Contusion
• Chest discomfort
• Fatigue
• Vessel puncture site bruise
• Vessel puncture site pain
• COVID-19
• Nasopharyngitis
• Pharyngitis streptococcal

Key clinical trials

• A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults (PHASE1)
• A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function (PHASE1)
• A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function (PHASE1)
• A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)
• A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults (PHASE1)
• A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants (PHASE1)
• A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-07328948 CI brief — competitive landscape report
• PF-07328948 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI